Celltrion Pharm Inc
The 068760-KQ stock trades on Korea Exchange Kosdaq
Company Description
Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 120 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world.
Drug Pipeline
Source: Celltrion Pharm Inc - 20220920
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
Herzuma
Breast Cancer
Reg/Com
Gastric Cancer
Reg/Com
Remsima
Ankylosing Spondylitis
Reg/Com
Crohn's Disease
Reg/Com
Psoriasis
Reg/Com
Psoriatic Arthritis
Reg/Com
Rheumatoid Arthritis
Reg/Com
Ulcerative Colitis
Reg/Com
Truxima
Chronic Lymphocytic Leukemia
Reg/Com
Lymphoma
Reg/Com
Rheumatoid Arthritis
Reg/Com
Wegener's Granulomatosis and Microscopic Polyangiitis
Reg/Com
0 Comments on 068760-KQ stock
Newest
Conversation